Key Takeaways BioMarin's Q3 EPS of $0.12 beat estimates but fell 87$776M, driven by Voxzogo and Palynziq growth, yet came in below consensus views.The company will divest Roctavian to sharpen its focus on strategic growth and future partnerships.BioMarin Pharmaceutical (BMRN) reported third-quarter 2025 adjusted earnings per share (EPS) of 12 cents against the Zacks Consensus Estimate of a loss of 15 cents. Quarterly earnings plummeted nearly ...